InterMune Inc. (ITMN)

[someconcerns]

GHMM,

I agree that it SHOULD be a slam dunk FDA approval and feel the US market will likely see slightly higher net product prices per patient-year. The 7 and 10 year exclusivity should be a sufficient time horizon.

However, I succumbed to temptation and sold my shares this morning, remembering how I didn't sell when the Europeans approved Esbriet shortly after the FDA denied approval. Kicked myself frequently as the shares dropped subsequently.

I do expect the price to drop to at least 30 and possibly to 25, when people start focusing on the timeline before FDA approval (application in the 3Q2014). I plan on buying back in, a luxury afforded by trading in a Roth account, although I too am typically a holder long-term.

I hope your forecast is accurate long-term and that mine is accurate short-term.

Steve